Transthyretin Amyloidosis Treatment Market to Grow with a CAGR of 7.26% through 2028

Increasing prevalence of transthyretin amyloidosis are expected to drive the Global Transthyretin Amyloidosis Treatment Market growth in the forecast period, 2024-2028.

According to TechSci Research report, “Transthyretin Amyloidosis Treatment Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Transthyretin Amyloidosis Treatment Market stood at USD 4.95 Billion in 2022 and is anticipated to grow with a CAGR of 7.26% through 2028. The COVID-19 pandemic negatively impacted the market growth owing to the decrease in a clinical trials for the drugs that could be used for the transthyretin amyloidosis treatment. For instance, in September 2020, an article published in the NCBI stated that a 74% of reduction has been witnessed in the average number of patients entering clinical trials. Patients suffering from transthyretin amyloidosis have a higher risk of mortality and morbidity owing to their age and ATTR- amyloidosis-related organ dysfunction. Therefore, proper characterization of risk and management implications are needed for the patients if they develop COVID-19. The implications of delayed diagnosis and interrupting treatment of patients should be balanced considering the risk of exposure to the virus in the healthcare setting. The increasing prevalence of transthyretin amyloidosis is anticipated to fuel market growth. Based on the article published on Prothena, it is estimated that around 50,000 people live with hATTR amyloidosis and about 400,000 people live with ATTRwt amyloidosis worldwide. The growing geriatric population in the country is anticipated to increase the prevalence of transthyretin amyloidosis over the forecast period. As per the NCBI data, an age-related form of amyloidosis primarily affects the heart and is also known as wild-type ATTR. For instance, in 2020, around 727 million people globally were aged 65 years and above. The geriatric population worldwide is growing substantially at a rate of 16.0% and is expected to reach 1.5 billion in 2050. Aging is considered a substantial risk factor for wild types of amyloidosis (ATTRwt).

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Transthyretin Amyloidosis Treatment Market”

The Global Transthyretin Amyloidosis Treatment Market is segmented into Type, Therapy ,Disease Type, Distribution Channel, and company.

Based on the Disease Type, the Hereditary transthyretin amyloidosis segment is anticipated to witness substantial market growth throughout the forecast period. The Global Transthyretin Amyloidosis Treatment Market is poised for significant growth, driven by the prevalence and recognition of hereditary transthyretin amyloidosis (hATTR). As genetic testing and diagnostic capabilities advance, there is a heightened awareness of hATTR, contributing to an expanding patient pool seeking treatment interventions. The distinct genetic basis of hATTR not only underscores the need for specialized therapies but also propels research and development efforts to address the unique challenges posed by hereditary forms of the disease. Pharmaceutical companies, recognizing the specific demands of hATTR, are investing in targeted therapeutic solutions tailored to the genetic underpinnings of the condition. This strategic focus on hereditary transthyretin amyloidosis not only ensures more effective treatments but also positions companies competitively in an evolving market landscape. Moreover, the genetic heritability of the disease emphasizes the importance of early intervention and proactive management, creating a sustained demand for treatment options.

Based on the Distribution Channel segment, the Hospital Pharmacies segment has been the dominant force in the market. The growth of the Global Transthyretin Amyloidosis Treatment Market is intricately linked to the pivotal role played by hospital pharmacies. As frontline healthcare providers, hospital pharmacies serve as crucial distribution hubs for specialized transthyretin amyloidosis treatments. The increasing prevalence of the condition, coupled with the demand for timely and effective interventions, positions hospital pharmacies as key contributors to market expansion. Hospital pharmacies play a central role in the continuum of care, ensuring the availability and accessibility of transthyretin amyloidosis treatments to patients within the healthcare facility. Their strategic location within hospitals streamlines the prescription fulfillment process, facilitating efficient and coordinated patient care. Moreover, hospital pharmacies often collaborate closely with healthcare professionals, enabling them to provide valuable insights into treatment options and patient adherence. This collaboration fosters a seamless integration of transthyretin amyloidosis therapies into comprehensive patient care plans.

Major companies operating in Global Transthyretin Amyloidosis Treatment Market are:

• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Ionis Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc.
• BridgeBio Pharma Inc.
• Bristol-Myers Squibb Company.
• Acrotech Biopharma.
• AstraZeneca Plc.
• SOM Biotech.

Download Free Sample Report

Customers can also request 10% free customization on this report

“The increasing prevalence of transthyretin amyloidosis, Initiatives undertaken by government and non-government bodies for creating awareness regarding the disease and its treatment benefits among people are expected to boost early diagnosis of disease, thereby increasing the treatment rate. Increasing novel drugs prescription, proper reimbursement policies, and higher treatment rates in the region are factors supporting transthyretin amyloidosis treatment market growth in the region. Moreover, major factors such as a large target population, good healthcare reforms, and an increase in disease awareness are expected to be the primary growth factors. Several market players are working toward the development and commercialization of drugs for the proper diagnosis and treatment of transthyretin amyloidosis.” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Transthyretin Amyloidosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (ATTR-PN, ATTR-CM), By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, By Competition”, has evaluated the future growth potential of Global Transthyretin Amyloidosis Treatment  Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Transthyretin Amyloidosis Treatment Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]